Minus - NCYT will have applied due diligence to Bruker, I'm sure! With the continuing poositive news flow and inevitable increase in sales, new, higher lows will be reached. China FDA approval this week. All IMO
Alamo - you have now moved the goalposts, but I'm happy to respond to your new point about the virus mutating. Make no mistake about it, the company's assay is the Golden Goose here. It will secure further FDAS, future business as well as sales. The scientists' at PrimerD will be working hard every day to ensure that the assay remains locked down. They will be alive to any mutations. The assay is not described as an 'unmatched [diagnostic] tool for nothing; a 'solid brick wall' meaning nothing can get past it.
Alamo - that's short sighted IMO. China like every other nation will have one eye on this virus returning. It will be buying and stockpiling reliable and accurate diagnostic tests over the coming months in readiness for the next outbreak of Covid-19. China FDA approval like future business and sales in China, is important to NCYT